Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate Update
New interim results from the U.S. REGAIN recurrent glioblastoma trial presented at the SNO 2026 An
New interim results from the U.S. REGAIN recurrent glioblastoma trial presented at the SNO 2026 An